Results 151 to 160 of about 626,377 (227)

Enzyme-Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. [PDF]

Chembiochem
Zhang Y, Wang L, Corcilius L, Reji AK, Payne RJ, Hong B, Durek T, Wang CK, Craik DJ.   +8 more
europepmc   +1 more source

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment. [PDF]

Front Cardiovasc Med
Lan J, Qiu Y, Wang S, Zhang Y, Cheng S, Chen S, Xing Y.   +6 more
europepmc   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. [PDF]

J Clin Med Res
Patel J, Shah S, Reddy A, Prajapati D, Pandya A, Sawhney S.   +5 more
europepmc   +1 more source

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment. [PDF]

J Am Heart Assoc
Yu L, Xiang B, Ren Y, Li Y, Xie J, Zhou X.   +5 more
europepmc   +1 more source

PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study. [PDF]

Eur Heart J Suppl
Gatto L, Di Bitonto MP, Scalia L, Biccirè FG, Prati F.   +4 more
europepmc   +1 more source

Synthesis of a PCSK9 Inhibitor [PDF]

Synfacts, 2018
openaire   +1 more source

Access to PCSK9 Inhibitors

Reviews in Cardiovascular Medicine, 2018
Jennifer G. Robinson, Norman E. Lepor, Seth J. Baum   +2 more
openaire   +1 more source

PCSK9 inhibitors: Going forward and beyond [PDF]

European Journal of Preventive Cardiology, 2020
openaire   +2 more sources